Candriam S.C.A. Sells 104,274 Shares of Halozyme Therapeutics, Inc. $HALO

Candriam S.C.A. lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 77.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,075 shares of the biopharmaceutical company’s stock after selling 104,274 shares during the period. Candriam S.C.A.’s holdings in Halozyme Therapeutics were worth $2,008,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in HALO. Measured Wealth Private Client Group LLC lifted its stake in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares during the last quarter. Larson Financial Group LLC raised its holdings in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the period. Harbour Investments Inc. raised its holdings in Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 372 shares during the period. Clearstead Advisors LLC lifted its position in Halozyme Therapeutics by 64.8% during the 4th quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 331 shares during the last quarter. Finally, Wexford Capital LP acquired a new position in Halozyme Therapeutics during the 3rd quarter worth $70,000. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $55,088,215. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 74,102 shares of company stock worth $5,205,798. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $75.05 on Wednesday. Halozyme Therapeutics, Inc. has a 1-year low of $55.64 and a 1-year high of $82.26. The firm has a market capitalization of $8.90 billion, a PE ratio of 27.00, a PEG ratio of 0.32 and a beta of 0.84. The business’s 50 day moving average is $71.32 and its 200-day moving average is $70.03. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same period in the prior year, the company posted $1.11 earnings per share. Halozyme Therapeutics’s revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on HALO. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Finally, Morgan Stanley dropped their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.